Dec 09,2024

The American Diabetes Association Releases Standards of Care in Diabetes -2025

The American Diabetes Association (ADA) has published its Standards of Care in Diabetes 2025, offering evidence-based guidelines for diagnosing, managing, and preventing diabetes and prediabetes. Key updates include expanded recommendations for continuous glucose monitoring (CGM) for type 2 diabetes, guidance on GLP-1 receptor agonists for heart and kidney health, and addressing medication shortages. The guidelines also emphasize improved approaches to nutrition, weight management, and mental health screening for people with diabetes. Endorsed by leading medical societies, the 2025 Standards aim to enhance outcomes for people with diabetes. Resources like a mobile app and CE-accredited materials are available to support healthcare professionals in delivering optimal care.

#cgm

View Analyst & Ambassador Comments
Go to original news
Dec 04,2024

United Kingdom Diabetes Device Market Forecast Report 2024-2032

The UK Diabetes Device Market is expected to grow from $1.05 billion in 2023 to $2 billion by 2032 at a 7.35% CAGR. This growth is fueled by rising diabetes prevalence, government support for advanced technologies, and an aging population needing better management solutions. Innovations in continuous glucose monitors (CGMs) and insulin pumps are enhancing patient care, while initiatives like updated NICE guidelines expand access to automated monitoring devices for children. Major players include Abbott, Roche, Medtronic, and Dexcom.

#cgm

View Analyst & Ambassador Comments
Go to original news
Nov 20,2024 TOP STORY

Medtronic receives FDA clearance for new InPen™ app, paving the way for its Smart MDI system launch with Simplera™ CGM

Medtronic has received FDA clearance for its new InPen™ app with missed meal dose detection, marking the launch of its Smart MDI (Multiple Daily Injection) system. This system integrates the InPen™ smart insulin pen with the Simplera™ CGM, Medtronic's first disposable, all-in-one continuous glucose monitor. The system provides real-time, personalized dosing recommendations, addressing missed or inaccurate insulin doses—a common challenge for diabetes patients on MDI therapy. It aims to simplify diabetes management, improve glucose control, and reduce health risks. A limited release will begin with existing customers, followed by a broader rollout.

REGULATORY FDA

#mobile app

#insulin pen

#cgm

View Analyst & Ambassador Comments
Go to original news
Nov 20,2024 TOP STORY

Insulet Announces Omnipod® 5 System is Now Compatible with Abbott’s FreeStyle Libre 2 Plus Sensor in the U.S.

Insulet Corporation has announced that its Omnipod 5 Automated Insulin Delivery (AID) System is now compatible with Abbott's FreeStyle Libre 2 Plus CGM in the U.S., making Omnipod 5 the most connected tubeless AID system available. The integration allows individuals with diabetes to use their preferred CGM while benefiting from Omnipod 5’s tubeless, automated insulin delivery. Omnipod 5 adjusts insulin every five minutes using its SmartAdjust™ technology, eliminating the need for multiple daily injections (MDI) and providing enhanced glucose control. This user-friendly, waterproof system is suitable for both type 1 and type 2 diabetes, offering discreet, wearable management and continuous communication with the CGM to correct for high glucose levels and protect against lows.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Nov 19,2024 TOP STORY

Health2Sync Partners with Singapore Health Promotion Board and Abbott to Launch Innovative DigiCoach Program Tackling Pre-diabetes and Obesity

Health2Sync has partnered with Singapore's Health Promotion Board (HPB) and Abbott to launch DigiCoach, an automated engagement program aimed at preventing diabetes in individuals with pre-diabetes or high BMI. Leveraging Abbott's Continuous Glucose Monitor (CGM) and the Health2Sync app, DigiCoach provides real-time glucose insights, personalized coaching, and lifestyle feedback. Participants use CGMs and Fitbits to track glucose patterns and exercise, receiving tailored recommendations for improved health. The 10-month pilot program, launched in July 2024, showcases public-private collaboration in addressing public health challenges and aims to create scalable solutions for better global health management.

COLLABORATION PARTNERSHIP

#cgm

#coaching

#product & service

View Analyst & Ambassador Comments
Go to original news
Nov 19,2024 TOP STORY

Dexcom and ŌURA Announce Strategic Partnership

DexCom and ŌURA have announced a strategic partnership to integrate Dexcom's glucose biosensing technology with ŌURA's smart ring data, providing users with a comprehensive view of metabolic health. The collaboration will combine glucose monitoring with biometrics such as sleep, stress, heart health, and activity, empowering users to better understand the links between lifestyle choices and glucose levels. Dexcom has also invested $75 million in ŌURA’s Series D funding. The partnership aims to launch its first app integration in early 2025, enabling personalized insights and promoting proactive health management.

COLLABORATION PARTNERSHIP

#cgm

#product & service

#mobile app

View Analyst & Ambassador Comments
Go to original news
Aug 14,2024

Saudi Arabia Digital Diabetes Management Market Trends Analysis Report 2024-2030

The "Saudi Arabia Digital Diabetes Management Market Size, Share & Trends Analysis Report" forecasts that the market will reach USD 208.3 million by 2030, growing at a compound annual growth rate (CAGR) of 8.9% from 2024 to 2030. The growth is driven by the rising prevalence of type 2 diabetes, influenced by sedentary lifestyles and poor dietary habits, along with the increased adoption of digital health solutions like wearable devices and mobile apps. In 2023, continuous glucose monitoring systems held the largest market share, while smart insulin pens and wearable devices are expected to see significant growth. The home settings segment, where individuals manage their diabetes privately, is also growing rapidly.

#mobile app

#cgm

View Analyst & Ambassador Comments
Go to original news
Aug 15,2024

Connected Diabetes Care Innovations and Growth Opportunities 2024: Funding, Emerging Technologies, and Key Partnerships Shaping the Future

The "Connected Diabetes Care: Innovations and Growth Opportunities" report explores advancements in continuous glucose monitors (CGMs), insulin delivery technologies, and artificial pancreas systems. It highlights the increasing preference for wearable CGMs over traditional finger-stick testing, especially for type 1 diabetes (T1D). The report also covers emerging digital diabetes care technologies, such as AI-driven apps that predict blood glucose levels and support overall well-being. Key growth opportunities identified include noninvasive glucose sensors, miniaturized artificial pancreas systems, and oral insulin. It also discusses funding trends, partnerships, and their impact on the future of diabetes care.

#cgm

View Analyst & Ambassador Comments
Go to original news
Feb 28,2024

Nova Scotia announces expanded coverage for insulin pumps and advanced glucose monitoring

Nova Scotia’s government has pledged $7.2 million to improve diabetes care by expanding access to digital diabetes devices, including continuous glucose monitors (CGMs) and insulin pumps, for residents managing type 1 and type 2 diabetes. The funding includes $5.9 million for CGM supplies through income-based and pharmacare programs and removes the age cap for insulin pump coverage, with an additional $1.3 million. These changes aim to assist approximately 4,000 people with glucose monitoring costs and provide 450 more individuals access to the Insulin Pump Program. This initiative aligns with JDRF Canada’s advocacy for broader access to life-saving diabetes technologies, supporting improved health outcomes and quality of life for those with diabetes in Nova Scotia.

#cgm

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Mar 21,2024

Newfoundland and Labrador expands access to continuous glucose monitoring program

Through its 2024 budget, Newfoundland and Labrador is expanding access to continuous glucose monitoring (CGM) for type 1 diabetes (T1D) patients. The program, which previously covered individuals under 18, will now include T1D patients up to age 25 in the provincial Insulin Pump Program and those pregnant with gestational diabetes. With $1.8 million in funding, the province aims to make CGM a permanent part of diabetes care, enhancing health outcomes and ease of management for more residents. JDRF Canada has praised the expansion, aligning with its ongoing advocacy for accessible diabetes technologies nationwide.

#cgm

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Subscribe to CGM